Taipei Veterans General Hospital, Taiwan Background and Aims: Idiopathic pulmonary fibrosis (IPF) is characterized by uncontrolled lung fibroblast proliferation, excessive extracellular collagen deposition and profibrotic mediators release such as vascular endothelial growth factor (VEGF). Nintedanib (NIN) and pirfenidone (PFD) are two drugs recently approved for treatment of IPF based on studies that showed their anti-fibrotic effects in vitro and clinically delayed disease deterioration. However, the detail therapeutic mechanism remains largely unknown. Lysophosphatidic acid (LPA) is a potent bioactive phospholipid in tissues, plasma and body fluids. Activation of LPA can induce diverse cellular responses, including cell proliferation, migration, and cytokine release through G-protein coupled LPA receptors (LPARs). Increased LPA level was observed in bronchoalveolar lavage fluid of IPF patients in recent studies, indicating its role in the pathophysiology of IPF. We hypothesized that both NIN and PFD could inhibit LPAinduced VEGF and collagen production released by lung fibroblasts. Conclusion: Both NIN and PFD inhibit LPA-induced VEGF and collagen production in human primary lung fibroblasts, suggesting their therapeutic mechanism involving LPA-regulated pulmonary fibrosis.
Taipei Veterans General Hospital, Taiwan Background and Aims: Idiopathic pulmonary fibrosis (IPF) is characterized by uncontrolled lung fibroblast proliferation, excessive extracellular collagen deposition and profibrotic mediators release such as vascular endothelial growth factor (VEGF). Nintedanib (NIN) and pirfenidone (PFD) are two drugs recently approved for treatment of IPF based on studies that showed their anti-fibrotic effects in vitro and clinically delayed disease deterioration. However, the detail therapeutic mechanism remains largely unknown. Lysophosphatidic acid (LPA) is a potent bioactive phospholipid in tissues, plasma and body fluids. Activation of LPA can induce diverse cellular responses, including cell proliferation, migration, and cytokine release through G-protein coupled LPA receptors (LPARs). Increased LPA level was observed in bronchoalveolar lavage fluid of IPF patients in recent studies, indicating its role in the pathophysiology of IPF. We hypothesized that both NIN and PFD could inhibit LPAinduced VEGF and collagen production released by lung fibroblasts. Background and Aims: Definitely, sirolimus can stabilize the pulmonary function of LAM patients, and decrease the level of serum biomarkers of VEGF-D level. However, researchers found that some mild and severe impairment of lung function in LAM patients who continued to use sirolimus continued to deteriorate.
Methods: According to whether there were affiliated with TSC1 or TSC2 mutations, they were divided into TSC 1/2 M (+) group included 21 cases and TSC1/2 M (-) group included 12 cases. After entering the group, sirolimus was given orally (maintenance of effective blood concentration 5~15 ng/ml ). At the same time, lung function, serum VEGF-D and other clinical datas were collected at baseline, follow up 3, 6, 12, 18, 24 months.
Results: Overall, sirolimus can stabilize the lung function indicators of Chinese LAM patients who suffered the moderate and severe pulmonary function damage, including FEV1, FVC, RV, TLC, DLCO and so on. Plus, sirolimus can reduce the serum VEGF-D level . Secondly, the subgroup analysis showed that sirolimus could stabilize and improve the pulmonary ventilation function and diffusion function in the TSC1/2 M(+) group of Chinese LAM population. The average monthly change of FEV1 increased by 5.57 AE 8.95 ml, the average monthly change of FVC increased by 9.04 AE 12.88 ml, and the average monthly variation of DLco increased by 0.04 AE 0.07 ml/mmHg/min. This group had a good response to sirolimus. The TSC1/2 M(-) group, responded poorly to sirolimus treatment. Finally, The level of serum VEGF-D in the TSC1/2 M(+) Group continued to decrease during the treatment.
Conclusion:
The long-term treatment of sirolimus can stabilize and improve the TSC1/2 M (+) group of Chinese LAM patients with FEV1, FVC and DLco, prevent the decrease of lung function and reduce the serum VEGF-D level. Background and Aims: Idiopathic pulmonary fibrosis (IPF) is a progressive, poor prognostic interstitial lung disease with median survival ranging from 2.5 to 3.5 years. We use two antifibrotic agents for IPF nowadays. Pirfenidone has been approved in December 2008 in Japan. The aim of this study is to clarify efficacy and tolerability of 10 yearsexperience using of pirfenidone for IPF.
Methods:
We retrospectively collected patients administered pirfenidone from December 2008 to April 2018. Baseline defined the day of starting pirfenidone. IPF was diagnosed by using the guideline of ATS/ERS/JRS/ALAT statement (AJRCCM 2011). IPF/UIP defined IPF confirmed by pathological findings of surgical lung biopsy (SLB) and clinical IPF defined IPF without SLB. Efficacy was evaluated decline of FVC after administration of pirfenidone, median survival time from starting pirfenidone in patients treated more than 52 weeks, and acute exacerbation rate in all patients with IPF. Tolerability was evaluated discontinuation ratio of pirfenidone at 52 weeks and whole period.
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